{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T17:35:44Z","timestamp":1789752944350,"version":"4.0.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,9,18]],"date-time":"2019-09-18T00:00:00Z","timestamp":1568764800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,9,18]],"date-time":"2019-09-18T00:00:00Z","timestamp":1568764800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n              <jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The emergence of Drug-Resistance Tuberculosis (DR-TB) is an increasing global public health problem. Lost to Follow-up (LTFU) from DR-TB treatment remains a major barrier to tuberculosis epidemic control and better treatment outcome. In Ethiopia, evidences on the incidence and predictors of LTFU are scarce. Thus, this study aimed to determine the incidence and identify the predictors of LTFU among DR-TB patients.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A retrospective follow-up study was conducted among a total of 332 DR-TB patients at the University of Gondar comprehensive specialized hospital. Data were retrieved from patient records from September 2010 to December 2017 and entered in to Epi-data\u00a04.2.0.0 and analysed using Stata14.1 software. The risk was estimated using the Nelson-Aalen cumulative hazard curve. A log-rank test was used for survival comparisons between categories of independent variables. The Gompertz regression model was fitted, and hazard ratio with a 95% confidence interval (CI) was used to measure the strength of associations. Variables with less than 0.05 <jats:italic>p<\/jats:italic>-values in the multivariable model were considered as significantly associated with LTFU.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Among a total of 332 patient records reviewed, 206 (62.05%) were male. The median age was 30\u2009years (Inter Quartile Range (IQR): 23\u201340). Forty-one (12.35%) of the participants had no history of TB treatment, while a quarter of were TB-HIV co-infected. Closely all (92.17%) of the patients had pulmonary tuberculosis. The median follow up time was 20.37\u2009months (IQR: 11.02, 21.80). Thirty-six (10.84%) patients were lost from follow-up with an incidence rate of 6.47 (95% CI: 4.67, 8.97)\/1000 Person Months (PM). Homelessness (Adjusted Hazard Ratio (AHR) =2.51, 95%CI: 1.15, 5.45) and treatment enrolment year from 2013 to 2014 (AHR\u2009=\u20093.25, 95% CI: 1.30, 8.13) were significant predictors of LTFU.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>This study indicated that LTFU among DR-TB registered patients was high in the first six months compared to subsequent months. Homelessness and year of treatment enrolment were independent predictors of LTFU, requiring more economic support to patients in order to ensure treatment completion. This result can be generalized to patients who are using DR-TB treatment in similar settings.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12879-019-4447-8","type":"journal-article","created":{"date-parts":[[2019,9,18]],"date-time":"2019-09-18T12:05:21Z","timestamp":1568808321000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Incidence and predictors of lost to follow-up among drug-resistant tuberculosis patients at University of Gondar Comprehensive Specialized Hospital, Northwest Ethiopia: a retrospective follow-up study"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9926-7797","authenticated-orcid":false,"given":"Getahun Molla","family":"Kassa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alemayehu Shimeka","family":"Teferra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haileab Fekadu","family":"Wolde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atalay Goshu","family":"Muluneh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehari Woldemariam","family":"Merid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,9,18]]},"reference":[{"key":"4447_CR1","volume-title":"Global strategy and targets for tuberculosis prevention, care and control after 2015","author":"World Health Organization","year":"2015","unstructured":"World Health Organization. Global strategy and targets for tuberculosis prevention, care and control after 2015. Geneva: WHO; 2015. Contract No: EB134\/12. 2017"},{"key":"4447_CR2","volume-title":"Global tuberculosis report","author":"World Health Organization","year":"2016","unstructured":"World Health Organization. Global tuberculosis report. 2016."},{"key":"4447_CR3","volume-title":"Global tuberculosis report","author":"World Health Organization","year":"2018","unstructured":"World Health Organization. Global tuberculosis report 2018."},{"key":"4447_CR4","first-page":"9241565055","volume-title":"Global tuberculosis report","author":"World Health Organization","year":"2015","unstructured":"World Health Organization. Global tuberculosis report; 2015. p. 9241565055."},{"key":"4447_CR5","volume-title":"Global tuberculosis report","author":"World Health Organization","year":"2017","unstructured":"World Health Organization. Global tuberculosis report 2017."},{"issue":"1","key":"4447_CR6","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1186\/s12889-015-1614-8","volume":"15","author":"D Lukoye","year":"2015","unstructured":"Lukoye D, Ssengooba W, Musisi K, Kasule GW, Cobelens FG, Joloba M, et al. Variation and risk factors of drug resistant tuberculosis in sub-Saharan Africa: a systematic review and meta-analysis. BMC Public Health. 2015;15(1):291.","journal-title":"BMC Public Health"},{"key":"4447_CR7","volume-title":"gaideline on programmatic management of drug resistant tuberculosis in ethiopia","author":"FDRE MoH","year":"2017","unstructured":"FDRE MoH. gaideline on programmatic management of drug resistant tuberculosis in ethiopia. 2017."},{"key":"4447_CR8","volume-title":"Second round anti-tuberculosis drug resistance surveillance in Ethiopia","author":"L Eshetu","year":"2014","unstructured":"Eshetu L, Beniam F, Abebaw K, Muluwork G, Zelalem Y, Ribka F, et al. Second round anti-tuberculosis drug resistance surveillance in Ethiopia,. 2014."},{"issue":"1","key":"4447_CR9","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1186\/s12879-017-2323-y","volume":"17","author":"S Eshetie","year":"2017","unstructured":"Eshetie S, Gizachew M, Dagnew M, Kumera G, Woldie H, Ambaw F, et al. Multidrug resistant tuberculosis in Ethiopian settings and its association with previous history of anti-tuberculosis treatment: a systematic review and meta-analysis. BMC Infect Dis. 2017;17(1):219.","journal-title":"BMC Infect Dis"},{"issue":"6","key":"4447_CR10","doi-asserted-by":"publisher","first-page":"805","DOI":"10.5588\/ijtld.11.0522","volume":"16","author":"B Tessema","year":"2012","unstructured":"Tessema B, Beer J, Emmrich F, Sack U, Rodloff A. First-and second-line anti-tuberculosis drug resistance in Northwest Ethiopia. Int J Tuberc Lung Dis. 2012;16(6):805\u201311.","journal-title":"Int J Tuberc Lung Dis."},{"key":"4447_CR11","volume-title":"Global tuberculosis report","author":"World Health Organization","year":"2014","unstructured":"World Health Organization. Global tuberculosis report 2014."},{"issue":"12","key":"4447_CR12","doi-asserted-by":"publisher","first-page":"e83480","DOI":"10.1371\/journal.pone.0083480","volume":"8","author":"EA Kendall","year":"2013","unstructured":"Kendall EA, Theron D, Franke MF, Van Helden P, Victor TC, Murray MB, et al. Alcohol, hospital discharge, and socioeconomic risk factors for default from multidrug resistant tuberculosis treatment in rural South Africa: a retrospective cohort study. PLoS One. 2013;8(12):e83480.","journal-title":"PLoS One"},{"issue":"9979","key":"4447_CR13","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1016\/S0140-6736(15)60570-0","volume":"385","author":"M Uplekar","year":"2015","unstructured":"Uplekar M, Weil D, Lonnroth K, Jaramillo E, Lienhardt C, Dias HM, et al. WHO\u2019s new end TB strategy. Lancet. 2015;385(9979):1799\u2013801.","journal-title":"Lancet"},{"issue":"8","key":"4447_CR14","doi-asserted-by":"publisher","first-page":"e0135802","DOI":"10.1371\/journal.pone.0135802","volume":"10","author":"RD Deshmukh","year":"2015","unstructured":"Deshmukh RD, Dhande D, Sachdeva KS, Sreenivas A, Kumar A, Satyanarayana S, et al. Patient and provider reported reasons for lost to follow up in MDRTB treatment: a qualitative study from a drug resistant TB Centre in India. PLoS One. 2015;10(8):e0135802.","journal-title":"PLoS One"},{"issue":"3","key":"4447_CR15","doi-asserted-by":"publisher","first-page":"491","DOI":"10.3201\/eid2203.151788","volume":"22","author":"TE Tupasi","year":"2016","unstructured":"Tupasi TE, Garfin AMCG, Kurbatova EV, Mangan JM, Orillaza-Chi R, Naval LC, et al. Factors associated with loss to follow-up during treatment for multidrug-resistant tuberculosis, the Philippines, 2012\u20132014. Emerg Infect Dis. 2016;22(3):491.","journal-title":"Emerg Infect Dis"},{"issue":"1","key":"4447_CR16","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1186\/s12879-017-2655-7","volume":"17","author":"J Wohlleben","year":"2017","unstructured":"Wohlleben J, Makhmudova M, Saidova F, Azamova S, Mergenthaler C, Verver S. Risk factors associated with loss to follow-up from tuberculosis treatment in Tajikistan: a case-control study. BMC Infect Dis. 2017;17(1):543.","journal-title":"BMC Infect Dis"},{"issue":"7","key":"4447_CR17","doi-asserted-by":"publisher","first-page":"e0132543","DOI":"10.1371\/journal.pone.0132543","volume":"10","author":"KS Shringarpure","year":"2015","unstructured":"Shringarpure KS, Isaakidis P, Sagili KD, Baxi R. Loss-to-follow-up on multidrug resistant tuberculosis treatment in Gujarat, India: the when and who of it. PLoS One. 2015;10(7):e0132543.","journal-title":"PLoS One"},{"issue":"3","key":"4447_CR18","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1111\/tmi.12826","volume":"22","author":"KA Alene","year":"2017","unstructured":"Alene KA, Viney K, McBryde ES, Tsegaye AT, Clements AC. Treatment outcomes in patients with multidrug-resistant tuberculosis in north-West Ethiopia. Tropical Med Int Health. 2017;22(3):351\u201362.","journal-title":"Tropical Med Int Health"},{"issue":"12","key":"4447_CR19","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1136\/thoraxjnl-2015-207374","volume":"70","author":"Daniel Meressa","year":"2015","unstructured":"Meressa D, Hurtado RM, Andrews JR, Diro E, Abato K, Daniel T, et al. Achieving high treatment success for multidrug-resistant TB in Africa: initiation and scale-up of MDR TB care in Ethiopia\u2014an observational cohort study. Thorax. 2015. \n                    https:\/\/doi.org\/10.1136\/thoraxjnl-2015-207374\n                    \n                  .","journal-title":"Thorax"},{"issue":"3","key":"4447_CR20","doi-asserted-by":"publisher","first-page":"1602308","DOI":"10.1183\/13993003.02308-2016","volume":"49","author":"D Falzon","year":"2017","unstructured":"Falzon D, Sch\u00fcnemann HJ, Harausz E, Gonz\u00e1lez-Angulo L, Lienhardt C, Jaramillo E, et al. World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update. Eur Respir J. 2017;49(3):1602308.","journal-title":"Eur Respir J"},{"key":"4447_CR21","unstructured":"World Health Organization. World health statistics 2016: monitoring health for the SDGs sustainable development goals. Geneva: World Health Organization; 2016."},{"issue":"2","key":"4447_CR22","doi-asserted-by":"publisher","first-page":"116","DOI":"10.5588\/pha.17.0013","volume":"7","author":"S Suryawanshi","year":"2017","unstructured":"Suryawanshi S, Shewade H, Nagaraja S, Nair S, Parmar M. Unfavourable outcomes among patients with MDR-TB on the standard 24-month regimen in Maharashtra, India. Public Health Action. 2017;7(2):116\u201322.","journal-title":"Public Health Action"},{"issue":"3","key":"4447_CR23","doi-asserted-by":"publisher","first-page":"e0118919","DOI":"10.1371\/journal.pone.0118919","volume":"10","author":"S Moyo","year":"2015","unstructured":"Moyo S, Cox HS, Hughes J, Daniels J, Synman L, De Azevedo V, et al. Loss from treatment for drug resistant tuberculosis: risk factors and patient outcomes in a community-based program in Khayelitsha, South Africa. PLoS One. 2015;10(3):e0118919.","journal-title":"PLoS One"},{"issue":"2","key":"4447_CR24","doi-asserted-by":"publisher","first-page":"S41","DOI":"10.5588\/pha.14.0048","volume":"4","author":"G Kuchukhidze","year":"2014","unstructured":"Kuchukhidze G, Kumar A, de Colombani P, Khogali M, Nanava U, Blumberg H, et al. Risk factors associated with loss to follow-up among multidrug-resistant tuberculosis patients in Georgia. Public Health Action. 2014;4(2):S41\u2013S6.","journal-title":"Public Health Action"},{"issue":"4","key":"4447_CR25","doi-asserted-by":"publisher","first-page":"441","DOI":"10.5588\/ijtld.13.0742","volume":"18","author":"H Cox","year":"2014","unstructured":"Cox H, Hughes J, Daniels J, Azevedo V, McDermid C, Poolman M, et al. Community-based treatment of drug-resistant tuberculosis in Khayelitsha, South Africa. Int J Tuberc Lung Dis. 2014;18(4):441\u20138.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"3","key":"4447_CR26","doi-asserted-by":"publisher","first-page":"299","DOI":"10.5588\/ijtld.12.0537","volume":"17","author":"A Toczek","year":"2013","unstructured":"Toczek A, Cox H, Du Cros P, Cooke G, Ford N. Strategies for reducing treatment default in drug-resistant tuberculosis: systematic review and meta-analysis. Int J Tuberc Lung Dis. 2013;17(3):299\u2013307.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"12","key":"4447_CR27","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1086\/588292","volume":"46","author":"MF Franke","year":"2008","unstructured":"Franke MF, Appleton SC, Bayona J, Arteaga F, Palacios E, Llaro K, et al. Risk factors and mortality associated with default from multidrug-resistant tuberculosis treatment. Clin Infect Dis. 2008;46(12):1844\u201351.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"4447_CR28","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.tube.2012.06.003","volume":"92","author":"EV Kurbatova","year":"2012","unstructured":"Kurbatova EV, Taylor A, Gammino VM, Bayona J, Becerra M, Danilovitz M, et al. Predictors of poor outcomes among patients treated for multidrug-resistant tuberculosis at DOTS-plus projects. Tuberculosis. 2012;92(5):397\u2013403.","journal-title":"Tuberculosis"},{"issue":"1","key":"4447_CR29","doi-asserted-by":"publisher","first-page":"23","DOI":"10.5588\/ijtld.16.0433","volume":"21","author":"T Tupasi","year":"2017","unstructured":"Tupasi T, Garfin A, Mangan J, Orillaza-Chi R, Naval L, Balane G, et al. Multidrug-resistant tuberculosis patients\u2019 views of interventions to reduce treatment loss to follow-up. Int J Tuberc Lung Dis. 2017;21(1):23\u201331.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"8","key":"4447_CR30","doi-asserted-by":"publisher","first-page":"584","DOI":"10.2471\/BLT.17.193375","volume":"95","author":"J Ho","year":"2017","unstructured":"Ho J, Byrne AL, Linh NN, Jaramillo E, Fox GJ. Decentralized care for multidrug-resistant tuberculosis: a systematic review and meta-analysis. Bull World Health Organ. 2017;95(8):584.","journal-title":"Bull World Health Organ"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-019-4447-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12879-019-4447-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-019-4447-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,17]],"date-time":"2020-09-17T12:13:26Z","timestamp":1600344806000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-019-4447-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,18]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["4447"],"URL":"https:\/\/doi.org\/10.1186\/s12879-019-4447-8","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,18]]},"assertion":[{"value":"18 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethical clearance was obtained from Institutional Review Board of College of Medicine and Health Sciences, University of Gondar. Permission letter was obtained from Amhara Public Health Institute, the Hospital administration, and the TB ward focal person. Personal identifiers were not included during data collection.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"817"}}